RxDoctor Payments Data

William Ferrell, MD

Neurology · Raleigh, NCNPI 1740212562

Payments from drug & device makers

$174,701in general payments, 2019–2025

Across 1,199 payments — averaging $145.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$156K
  • UCB, Inc.$1K
  • Amgen$1K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Sanofi$997
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$8894%
  • Speaking & faculty fees$410%
  • Food & beverage$21,63595%
  • Education$2601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)266$156,025
UCB, Inc.65$1,435
Amgen(2 entities)53$1,312
Novartis75$1,268
Teva Pharmaceuticals USA, Inc.65$1,050
Sanofi33$997
AstraZeneca(2 entities)41$970
TG Therapeutics, Inc.31$923
Lundbeck LLC34$763
Pfizer33$632
Neurocrine Biosciences, Inc.37$608
Neurelis, Inc.30$607
Genentech USA, Inc.32$553
Eisai Inc.31$544
Biogen29$537
Lilly USA, LLC28$454
Impel Pharmaceuticals Inc.22$357
SK Life Science, Inc.11$353
Biohaven Pharmaceuticals, Inc.11$350
Merz Pharmaceuticals, LLC16$344
Argenx US, Inc.14$281
Bristol Myers Squibb18$280
Axsome Therapeutics, Inc.13$240
Johnson & Johnson(2 entities)10$192
Jazz Pharmaceuticals Inc.11$190
Biohaven Pharmaceutical Holding Company Ltd.10$163
Grifols USA, LLC7$156
CSL Behring8$151
Boston Scientific3$147
Amneal Pharmaceuticals LLC8$145
Upsher-smith Laboratories LLC8$140
Sunovion Pharmaceuticals Inc.9$138
EMD Serono, Inc.8$132
Ipsen Biopharmaceuticals, Inc7$127
MDD US Operations, LLC7$121
Merz North America, Inc.3$116
Assertio Therapeutics, Inc.8$107
Acorda Therapeutics, Inc7$104
Avion Pharmaceuticals6$100
Bausch Health US, LLC5$98
Otsuka America Pharmaceutical, Inc.5$94
Acadia Pharmaceuticals Inc7$93
Avanir Pharmaceuticals, Inc.5$88
Mallinckrodt Hospital Products Inc.4$82
GE HealthCare6$76
Averitas Pharma Inc.3$70
Corium, LLC4$66
Banner Life Sciences, LLC3$66
Adamas Pharmaceuticals, Inc.4$57
Aucta Pharmaceuticals, Inc.4$57
Microtransponder, Inc.3$56
Tanabe Pharma America, Inc.2$49
Takeda Pharmaceuticals U.S.A., Inc.2$47
Supernus Pharmaceuticals, Inc.3$45
ANI Pharmaceuticals, Inc.2$41
Catalyst Pharmaceuticals, Inc.2$41
Mallinckrodt Enterprises LLC3$39
Alnylam Pharmaceuticals Inc.2$38
Sumitomo Pharma America, Inc.2$36
Arbor Pharmaceuticals, Inc.2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$174,701 in reported general payments places this provider in the 85th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,411,697
Medicare patients
295
Services billed
38,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$216,902
Aimovig AutoinjectorErenumab-Aooe69$61,426
UbrelvyUbrogepant26$43,680
Emgality PenGalcanezumab-Gnlm18$17,103
Ajovy AutoinjectorFremanezumab-Vfrm20$16,422
Sumatriptan Succinate47$10,084
Memantine Hcl140$4,760
Donepezil Hcl208$2,418
Entacapone22$2,051
Gabapentin100$2,013
Carbidopa-Levodopa ErCarbidopa/Levodopa21$1,958
Pyridostigmine Bromide20$1,929
RizatriptanRizatriptan Benzoate74$1,718
Azathioprine12$1,450
Propranolol Hcl ErPropranolol Hcl32$1,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$47$216,90226 claims
AbbVieUbrelvy$156,025$43,68026 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$145$1,92920 claims
Upsher-smith Laboratories LLCTopiramate$140$39031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 566 neurology providers in North Carolina.

Other neurology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →